11/29/2011 9:33:27 AM
CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUSTM respiratory delivery platform, announced today the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In addition, Civitas revealed today that the company’s lead drug candidate for Parkinson’s disease is CVT-301, an inhaled formulation of levodopa (L-dopa). The grant from MJFF will support the clinical development of CVT-301, which has the potential to produce rapid, consistent and durable relief from debilitating motor fluctuations associated with Parkinson’s disease.
comments powered by